

# Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

<https://marketpublishers.com/r/R4A0D13D4DB9EN.html>

Date: March 2021

Pages: 57

Price: US\$ 2,000.00 (Single User License)

ID: R4A0D13D4DB9EN

## Abstracts

Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and

features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Restless Legs Syndrome (Central Nervous

System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

- Introduction
- Global Markets Direct Report Coverage
- Restless Legs Syndrome - Overview
- Restless Legs Syndrome - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Restless Legs Syndrome - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Restless Legs Syndrome - Companies Involved in Therapeutics Development
  - Axim Biotechnologies Inc
  - Bioprojet SCR
  - Hisamitsu Pharmaceutical Co Inc
  - Luye Pharma Group Ltd
  - NLS Pharma Group
  - Omeros Corp
  - Relmada Therapeutics Inc
  - Seelos Therapeutics, Inc.
  - Serina Therapeutics Inc
  - Vifor Pharma Ltd
- Restless Legs Syndrome - Drug Profiles
  - (cannabidiol + dronabinol) - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - aplindore fumarate - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - BP-1.4979 - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-03009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REL-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropinirole hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Restless Legs Syndrome - Dormant Projects

Restless Legs Syndrome - Discontinued Products

Restless Legs Syndrome - Product Development Milestones

Featured News & Press Releases

Jan 04, 2021: Luye Pharma Group: LY03009 commenced phase I clinical trial in Australia

Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)

Mar 25, 2013: US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson's disease and restless leg syndrome

Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplineore In Restless Legs Syndrome And Parkinson's Disease

Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Restless Legs Syndrome, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, 2021  
Restless Legs Syndrome - Pipeline by Bioprojet SCR, 2021  
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2021  
Restless Legs Syndrome - Pipeline by Luye Pharma Group Ltd, 2021  
Restless Legs Syndrome - Pipeline by NLS Pharma Group, 2021  
Restless Legs Syndrome - Pipeline by Omeros Corp, 2021  
Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, 2021  
Restless Legs Syndrome - Pipeline by Seelos Therapeutics, Inc., 2021  
Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, 2021  
Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, 2021  
Restless Legs Syndrome - Dormant Projects, 2021  
Restless Legs Syndrome - Discontinued Products, 2021



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Restless Legs Syndrome, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/R4A0D13D4DB9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R4A0D13D4DB9EN.html>